Literature DB >> 18297619

[Zonisamide in refractory essential tremor].

P E Bermejo1, C Ruiz-Huete, R Dorado, B Anciones.   

Abstract

INTRODUCTION: Essential tremor is one of the most frequent movement disorders. It is characterized by postural and action tremor that may affect different regions of the body. Among current treatments propranolol and primidone are included. However, these two drugs have demonstrated a limited efficacy and several adverse events. Additionally, they are contraindicated in patients with cardiac insufficiency and several respiratory diseases. New antiepileptic drugs are revealing as a possibility in the treatment of this disease. AIM. To evaluate efficacy and tolerability of zonisamide in the treatment of essential tremor. PATIENTS AND METHODS: We perform a retrospective study about 13 patients with essential tremor refractory to an average of 2.8 drugs. Age, sex, zonisamide dosage, adverse events, duration and response to the treatment before and after the treatment were collected and analysed. Average zonisamide dosage was 215 mg/day and average duration of the treatment was 121 days.
RESULTS: Nine of 13 patients included in our study experienced a good response. A positive response was understood as a decrease on the limitation of daily activities and an improvement on neurological examination. Zonisamide was well tolerated and no patient abandoned the study for this reason.
CONCLUSIONS: Our data suggest that zonisamide is effective and well tolerated in the treatment of essential tremor. Placebo-controlled and bigger studies are warranted to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297619

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  7 in total

1.  A review of the use of zonisamide in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Buenaventura Anciones
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

2.  Zonisamide in managing impulse control disorders in Parkinson's disease.

Authors:  Pedro Emilio Bermejo; Cristina Ruiz-Huete; Buenaventura Anciones
Journal:  J Neurol       Date:  2010-05-28       Impact factor: 4.849

Review 3.  Pharmacological management of essential tremor.

Authors:  Reza Sadeghi; William G Ondo
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

4.  Nightmare-enacting behavior responding to zonisamide in early Parkinson's disease.

Authors:  Hiroshi Kataoka; Satoshi Ueno
Journal:  Case Rep Neurol       Date:  2012-01-25

Review 5.  Zonisamide for essential tremor.

Authors:  Elisa Bruno; Alessandra Nicoletti; Graziella Filippini; Graziella Quattrocchi; Carlo Colosimo; Mario Zappia
Journal:  Cochrane Database Syst Rev       Date:  2017-08-24

6.  Protective effect of melatonin against zonisamide-induced reproductive disorders in male rats.

Authors:  Wagdy K B Khalil; Faiza Abdu
Journal:  Arch Med Sci       Date:  2013-12-05       Impact factor: 3.318

Review 7.  Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.

Authors:  Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez; Félix J Jiménez-Jiménez
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.